Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | GHSD HD18 study: reducing chemotherapy toxicity in advanced stage Hodgkin lymphoma

Peter Borchmann • 24 Jun 2017
EHA 2017
Hodgkin Lymphoma

Press brief by Peter Borchmann, MD from the University Hospital Cologne, Germany at the European Hematology Association (EHA) 2017 meeting, held in Madrid, Spain.

More from Peter Borchmann

BrECADD regimen is superior in treating advanced HL: results from the HD21 trial
6:37
BrECADD regimen is superior in treating advanced HL: results from the HD21 trial
Peter Borchmann • 14 Jun 2024
PET-guided treatment: the new standard of care in Hodgkin lymphoma?
1:34
PET-guided treatment: the new standard of care in Hodgkin lymphoma?
Peter Borchmann • 15 Jun 2023
Promising results from the SWOG S1826 trial: nivo-AVD versus BV-AVD in patients with cHL
1:26
Promising results from the SWOG S1826 trial: nivo-AVD versus BV-AVD in patients with cHL
Peter Borchmann • 15 Jun 2023
Insights into the BrECADD regimen in HL & results from the GHSG HD21 study
2:27
Insights into the BrECADD regimen in HL & results from the GHSG HD21 study
Peter Borchmann • 15 Jun 2023

Related Videos

Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
1:16
Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
1:10
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
1:42
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
Cathy Burton • 6 Jul 2026
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
2:36
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
Cathy Burton • 14 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals